BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/19/2026 12:16:38 PM | Browse: 7 | Download: 2
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Enterochromaffin-like cell hyperplasia grade as a surveillance marker in type 1 gastric neuroendocrine tumors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ru-Ao Chen, Yan-Fen Shi, Yu-Yang Wang, Yan-Mei Li, Wen-Juan Guo, Fu-Huan Yu, Ying-Ying Chen, Jie Luo, Huang-Ying Tan and Chao Deng |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the National High Level Hospital Clinical Research Funding |
2025-NHLHCRF-PY-11 |
|
| Corresponding Author |
Huang-Ying Tan, PhD, Professor, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China. tanhuangying@zryhyy.com.cn |
| Key Words |
Type 1 gastric neuroendocrine tumors; Enterochromaffin-like cell hyperplasia; Disease progression; Traditional Chinese medicine; Prognostic model; Autoimmune thyroid disease; Retrospective cohort study |
| Core Tip |
This retrospective cohort study of 107 patients with type 1 gastric neuroendocrine tumors found that enterochromaffin-like (ECL) cell hyperplasia grade is closely associated with tumor burden, serving as a surveillance marker rather than an independent prognostic factor. A four-variable nomogram incorporating neuroendocrine tumors number ≥ 3, autoimmune thyroid disease, anemia, and intrinsic factor antibody positivity stratified patients into three risk groups. Autoimmune thyroid disease was protective, whereas traditional Chinese medicine use showed a favorable but preliminary association. These findings support ECL-guided surveillance with risk-stratified management, pending external validation. |
| Citation |
Chen RA, Shi YF, Wang YY, Li YM, Guo WJ, Yu FH, Chen YY, Luo J, Tan HY, Deng C. Enterochromaffin-like cell hyperplasia grade as a surveillance marker in type 1 gastric neuroendocrine tumors. World J Gastroenterol 2026; In press
|
| PDF |
126723-in-press.pdf
|
 |
Received |
|
2026-08-12 03:46 |
 |
Peer-Review Started |
|
2026-08-12 03:47 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2026-08-25 01:47 |
 |
Revised |
|
2026-09-16 17:43 |
 |
Publication Fee Transferred |
|
2026-09-29 07:38 |
 |
Editorial Processing by Scientific Editor |
|
2026-11-19 06:49 |
 |
Final Academic Decision by Editor-in-Chief |
|
|
 |
Publication Technical Verification by Editorial Office Director |
|
2026-11-19 12:16 |
 |
Articles in Press |
|
2026-11-19 12:16 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.